Compare Aurobindo Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA STRIDES PHARMA SCIENCE AUROBINDO PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 9.0 5.1 174.0% View Chart
P/BV x 1.7 0.8 208.3% View Chart
Dividend Yield % 0.6 0.6 104.0%  

Financials

 AUROBINDO PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
AUROBINDO PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs8301,147 72.4%   
Low Rs527642 82.1%   
Sales per share (Unadj.) Rs333.9317.2 105.2%  
Earnings per share (Unadj.) Rs40.47.8 514.4%  
Cash flow per share (Unadj.) Rs51.825.1 206.6%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.40.2 164.8%  
Book value per share (Unadj.) Rs237.1274.3 86.4%  
Shares outstanding (eoy) m585.9189.50 654.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.02.8 72.1%   
Avg P/E ratio x16.8114.0 14.7%  
P/CF ratio (eoy) x13.135.7 36.7%  
Price / Book Value ratio x2.93.3 87.8%  
Dividend payout %6.225.5 24.3%   
Avg Mkt Cap Rs m397,56980,058 496.6%   
No. of employees `00017.92.5 712.2%   
Total wages/salary Rs m25,8494,341 595.5%   
Avg. sales/employee Rs Th10,956.911,325.8 96.7%   
Avg. wages/employee Rs Th1,447.71,731.4 83.6%   
Avg. net profit/employee Rs Th1,324.3280.1 472.9%   
INCOME DATA
Net Sales Rs m195,63628,394 689.0%  
Other income Rs m1,553941 165.1%   
Total revenues Rs m197,18929,334 672.2%   
Gross profit Rs m39,5193,965 996.6%  
Depreciation Rs m6,6801,540 433.6%   
Interest Rs m2,6261,962 133.8%   
Profit before tax Rs m31,7671,403 2,263.9%   
Minority Interest Rs m270-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m-881-436 202.1%   
Tax Rs m7,26997 7,470.2%   
Profit after tax Rs m23,645702 3,367.8%  
Gross profit margin %20.214.0 144.6%  
Effective tax rate %22.96.9 330.0%   
Net profit margin %12.12.5 488.8%  
BALANCE SHEET DATA
Current assets Rs m153,64524,836 618.6%   
Current liabilities Rs m120,42918,993 634.1%   
Net working cap to sales %17.020.6 82.5%  
Current ratio x1.31.3 97.6%  
Inventory Days Days13571 190.5%  
Debtors Days Days64113 56.2%  
Net fixed assets Rs m103,90934,289 303.0%   
Share capital Rs m586895 65.5%   
"Free" reserves Rs m138,32223,651 584.9%   
Net worth Rs m138,90824,546 565.9%   
Long term debt Rs m1,80015,513 11.6%   
Total assets Rs m264,54465,437 404.3%  
Interest coverage x13.11.7 763.7%   
Debt to equity ratio x00.6 2.0%  
Sales to assets ratio x0.70.4 170.4%   
Return on assets %9.94.1 243.9%  
Return on equity %17.02.9 595.1%  
Return on capital %23.86.9 345.7%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31615,697 620.0%   
Fx outflow Rs m40,589735 5,519.3%   
Net fx Rs m56,72714,962 379.1%   
CASH FLOW
From Operations Rs m16,2201,871 867.1%  
From Investments Rs m-28,7685,826 -493.8%  
From Financial Activity Rs m19,191-10,157 -188.9%  
Net Cashflow Rs m6,656-2,615 -254.6%  

Share Holding

Indian Promoters % 54.1 27.7 195.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 37.8 21.0%  
FIIs % 27.7 8.6 322.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 25.9 39.4%  
Shareholders   69,601 56,241 123.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Nifty Below 8,300 Mark, Fiscal Deficit in Feb, Maruti Suzuki Sales, and Top Cues in Focus Today(Pre-Open)

Indian share markets extended losses in the first trading session of FY21 on Wednesday. Losses were seen as the number of coronavirus cases in the country continued to rise.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout...(The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 1, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS